Tibotec Cost Recovery Distribution Program
Johnson & Johnson’s Tibotec subsidiary makes Tibozole TM Miconazole MAT, a muco-adhesive buccal tablet that can treat oral thrush in AIDS patients. To date, Tibotec has sold at cost or donated over two million patient treatments of Miconazole nitrate 10 mg MAT for use in sub-Saharan Africa. Of these, more than 1,300,000 treatment units have been sold to international procurement agencies for distribution in resource poor settings, through Tibotec’s Cost recovery distribution program. Tibotec collaborates with major not-for-profit suppliers to the developing world, such as IDA and MSF, to maximize access and ensure sustainable product supply. Pilot collaborations with voluntary organizations have led to an increase in donations of patient treatments in a number of sub-Saharan African countries.
One community-based program benefiting from at-cost miconazole is the Comprehensive Community Based Rehabilitation center in Dar es Salaam, Tanzania (CCBRT). Dr. Geert Vanneste, Medical Director of the holistic HIV program at CCBRT, said “the product has really provided us with a convenient, fast acting topical product, which can be used at the lowest level of care, and represents a real advance in the armamentarium for our home based care workers.” The home based care providers working in the program have also spoken out regarding the product benefits: its efficacy, minimal side effects and good compliance.